Phase II study exploring reduction method of Lenvatinib for the patients with advanced hepatocellular carcinoma
Not Applicable
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000032400
- Lead Sponsor
- Kanazawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
Refractory ascites or pleural effusion, history of hepatic encephalopathy, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; allergy for Lenvatinib, or contrast agent of CT or/and MRI
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, Relative dose intensity
- Secondary Outcome Measures
Name Time Method